MX2017000307A - Tratamiento de leucemia con inhibidores de histona deacetilasa. - Google Patents
Tratamiento de leucemia con inhibidores de histona deacetilasa.Info
- Publication number
- MX2017000307A MX2017000307A MX2017000307A MX2017000307A MX2017000307A MX 2017000307 A MX2017000307 A MX 2017000307A MX 2017000307 A MX2017000307 A MX 2017000307A MX 2017000307 A MX2017000307 A MX 2017000307A MX 2017000307 A MX2017000307 A MX 2017000307A
- Authority
- MX
- Mexico
- Prior art keywords
- leukemia
- treatment
- subject
- histone deacetylase
- need
- Prior art date
Links
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title abstract 5
- 239000003276 histone deacetylase inhibitor Substances 0.000 title abstract 5
- 208000032839 leukemia Diseases 0.000 title abstract 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 2
- 229960002756 azacitidine Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En la presente se brindan combinaciones que comprenden un inhibidor de HDAC y azacitidina, para el tratamiento de leucemia en un sujeto que lo necesita. En la presente se brindan combinaciones que comprenden un inhibidor de HDAC y azacitidina, para el tratamiento de leucemia mielógena aguda en un sujeto que lo necesita. En la presente también se brindan métodos para tratar la leucemia en un sujeto que lo necesita, que comprenden administrarle al sujeto una cantidad eficaz de la combinación anterior o un inhibidor de HDAC, así como métodos para tratar la leucemia miel6gena aguda en un sujeto que lo necesita, que comprenden administrarle al sujeto una cantidad eficaz de la combinación anterior o un inhibidor de HDAC.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462021473P | 2014-07-07 | 2014-07-07 | |
US201462061233P | 2014-10-08 | 2014-10-08 | |
US201562147218P | 2015-04-14 | 2015-04-14 | |
PCT/US2015/039225 WO2016007423A1 (en) | 2014-07-07 | 2015-07-06 | Treatment of leukemia with histone deacetylase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017000307A true MX2017000307A (es) | 2017-11-23 |
Family
ID=55064739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017000307A MX2017000307A (es) | 2014-07-07 | 2015-07-06 | Tratamiento de leucemia con inhibidores de histona deacetilasa. |
Country Status (13)
Country | Link |
---|---|
US (1) | US9833466B2 (es) |
EP (1) | EP3166603B1 (es) |
JP (1) | JP6952602B2 (es) |
KR (1) | KR20170044097A (es) |
CN (1) | CN107205988A (es) |
AU (1) | AU2015288060A1 (es) |
BR (1) | BR112017000301A2 (es) |
CA (1) | CA2954522A1 (es) |
EA (1) | EA201790142A1 (es) |
IL (1) | IL249935A0 (es) |
MX (1) | MX2017000307A (es) |
SG (1) | SG11201700094TA (es) |
WO (1) | WO2016007423A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI600638B (zh) * | 2010-01-22 | 2017-10-01 | 艾斯特隆製藥公司 | 作爲蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法 |
JP2015515279A (ja) | 2012-04-19 | 2015-05-28 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療 |
US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
US9403779B2 (en) | 2013-10-08 | 2016-08-02 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors |
EP4137135B1 (en) | 2013-10-24 | 2024-06-05 | Mayo Foundation for Medical Education and Research | Treatment of polycystic diseases with an hdac6 inhibitor |
JP6535670B2 (ja) | 2013-12-03 | 2019-06-26 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | ヒストンデアセチラーゼ阻害剤と免疫調節薬の組合せ |
US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
MX2017007623A (es) | 2014-12-12 | 2018-09-26 | Regenacy Pharmaceuticals Llc | Derivados de piperidina como inhibidores de hdac1/2. |
WO2016172734A1 (en) * | 2015-04-24 | 2016-10-27 | California Institute Of Technology | Reactivation of x chromosome genes |
CN107922352B (zh) | 2015-06-08 | 2021-08-06 | 埃斯泰隆制药公司 | 制备蛋白质脱乙酰酶抑制剂的方法 |
JP6816036B2 (ja) | 2015-06-08 | 2021-01-20 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | ヒストン脱アセチル化阻害剤の結晶形態 |
WO2017184774A1 (en) | 2016-04-19 | 2017-10-26 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia |
AR109250A1 (es) * | 2016-06-09 | 2018-11-14 | Acetylon Pharmaceuticals Inc | Métodos de uso y combinaciones farmacéuticas de inhibidores de hdac con inhibidores de proteínas bet |
US11324744B2 (en) | 2016-08-08 | 2022-05-10 | Acetylon Pharmaceuticals Inc. | Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies |
EP3532044A4 (en) | 2016-10-27 | 2020-07-29 | California Institute of Technology | HDAC-INHIBITING COMPOSITIONS FOR REACTIVATING THE X-CHROMOSOME |
US11497746B2 (en) | 2016-11-23 | 2022-11-15 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof |
CN106810460A (zh) * | 2016-12-30 | 2017-06-09 | 苏州诚和医药化学有限公司 | 一种4‑[2‑(二甲基氨基)乙氧基]苄胺的制备方法 |
SG11202002753QA (en) | 2017-10-26 | 2020-05-28 | Nat Univ Singapore | A new approach for universal monitoring of minimal residual disease in acute myeloid leukemia |
JP7021503B2 (ja) * | 2017-11-02 | 2022-02-17 | 三菱瓦斯化学株式会社 | 脂肪族ジアミンの製造方法 |
CN116421598A (zh) * | 2022-01-11 | 2023-07-14 | 苏州亚盛药业有限公司 | 用于治疗aml-mrc和mds的方法 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3549633A (en) | 1968-11-20 | 1970-12-22 | Merck & Co Inc | Process for preparation of 1-h-imidazo (4,5-b)pyrazin-2-ones |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
EP1280764B1 (en) | 2000-03-24 | 2010-11-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US20050119305A1 (en) | 2001-03-21 | 2005-06-02 | Masao Naka | Il-6 production inhibitors |
US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
ATE375331T1 (de) | 2001-11-01 | 2007-10-15 | Janssen Pharmaceutica Nv | Amidderivate als inhibitoren der glycogensynthasekinase-3-beta |
EA007272B1 (ru) | 2002-03-13 | 2006-08-25 | Янссен Фармацевтика Н. В. | Новые ингибиторы гистондеацетилазы |
MXPA04007776A (es) | 2002-03-13 | 2004-10-15 | Janssen Pharmaceutica Nv | Derivados de sulfonilamino como nuevos inhibidores de histona deacetilasa. |
TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7132425B2 (en) | 2002-12-12 | 2006-11-07 | Hoffmann-La Roche Inc. | 5-substituted-six-membered heteroaromatic glucokinase activators |
US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
EP1608628A2 (en) | 2003-03-17 | 2005-12-28 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
WO2005012261A1 (de) | 2003-07-24 | 2005-02-10 | Basf Aktiengesellschaft | 2-substituierte pyrimidine |
BRPI0414581C1 (pt) | 2003-09-22 | 2021-05-25 | Mei Pharma Inc | composto, composição farmacêutica compreendendo o referido composto e uso do referido composto |
KR101153335B1 (ko) | 2003-09-24 | 2012-07-05 | 메틸진 인코포레이티드 | 히스톤 데아세틸라제의 억제제 |
EP1745022B1 (en) | 2004-04-05 | 2014-08-13 | Aton Pharma, Inc. | Histone deacetylase inhibitor prodrugs |
WO2006102557A2 (en) | 2005-03-22 | 2006-09-28 | The President And Fellows Of Harvard College | Treatment of protein degradation disorders |
GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
JP2009509923A (ja) | 2005-08-26 | 2009-03-12 | メシルジーン、インコーポレイテッド | ヒストンデアセチラーゼのベンゾジアゼピン及びベンゾピペラジン類似体阻害薬 |
CN101300245B (zh) | 2005-11-01 | 2011-06-01 | 住友化学株式会社 | 6,6-二甲基-3-氧杂二环[3.1.0]己烷-2-酮的制造方法 |
MX2008010035A (es) | 2006-02-07 | 2008-10-17 | Astellas Pharma Inc | Compuestos de n-hidroxiacrilamida. |
JP5441416B2 (ja) | 2006-02-14 | 2014-03-12 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 二官能性ヒストンデアセチラーゼインヒビター |
EP2007720B1 (en) | 2006-04-07 | 2013-12-25 | MethylGene Inc. | Benzamide derivatives as inhibitors of histone deacetylase |
JP2009535333A (ja) | 2006-04-26 | 2009-10-01 | メルク エンド カムパニー インコーポレーテッド | 二置換アニリン化合物 |
AU2007248656B2 (en) | 2006-05-03 | 2013-04-04 | Dana-Farber Cancer Institute, Inc. | Histone deacetylase and tubulin deacetylase inhibitors |
WO2007144341A1 (en) | 2006-06-12 | 2007-12-21 | Vrije Universiteit Brussel | Differentiation of rat liver epithelial cells into hepatocyte-like cells |
ES2288802B1 (es) | 2006-07-07 | 2008-12-16 | Universidad De Granada | Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas. |
AU2007296743B2 (en) | 2006-09-11 | 2012-02-16 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
BRPI0718089A2 (pt) | 2006-10-28 | 2013-11-05 | Methylgene Inc | Composto, uso do composto, composição, e, métodos para inibir histona desacetilase e para tratar uma doença de expansão da poliglutamina |
WO2008053131A1 (en) | 2006-10-30 | 2008-05-08 | Chroma Therapeutics Ltd. | Hydroxamates as inhibitors of histone deacetylase |
JP2010519287A (ja) | 2007-02-21 | 2010-06-03 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | α−ハロシクロプロピルカルボキシ化合物およびα−アルキルシクロプロピルカルボキシ化合物ならびにそれらの使用 |
JP2010120852A (ja) | 2007-03-09 | 2010-06-03 | Daiichi Sankyo Co Ltd | 新規なジアミド誘導体 |
CN101861151B (zh) | 2007-09-14 | 2014-08-13 | 梅特希尔基因公司 | 使用组蛋白脱乙酰基酶hdac1、hdac2和/或hdac3的选择性抑制剂和微管稳定剂的癌症组合治疗 |
KR101325374B1 (ko) | 2008-02-19 | 2013-11-08 | 가부시키가이샤 오츠까 세이야꾸 고죠 | 신체 기능의 회복에 유용한 경구 또는 경장 조성물 |
WO2009137503A1 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Hdac inhibitors and uses thereof |
US20110288070A1 (en) | 2008-05-05 | 2011-11-24 | ROGERS Kathryn | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
WO2010009155A2 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Fused heterocyclyc inhibitor compounds |
US8440716B2 (en) | 2008-07-23 | 2013-05-14 | President And Fellows Of Harvard College | Deacetylase inhibitors and uses thereof |
KR101430424B1 (ko) | 2009-01-08 | 2014-08-14 | 쿠리스 인코퍼레이션 | 아연 결합 모이어티를 갖는 포스포이노시티드 3-키나제 억제제 |
US8716326B2 (en) | 2009-05-15 | 2014-05-06 | Korea Research Institute Of Chemical Technology | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same |
ES2736200T3 (es) | 2009-07-22 | 2019-12-26 | Univ Illinois | Inhibidores de HDAC y métodos terapéuticos que utilizan los mismos |
WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
US20130040998A1 (en) | 2010-01-08 | 2013-02-14 | Dana-Farber Cancer Institute, Inc. | Fluorinated hdac inhibitors and uses thereof |
TWI600638B (zh) * | 2010-01-22 | 2017-10-01 | 艾斯特隆製藥公司 | 作爲蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法 |
EP2571352A4 (en) | 2010-05-21 | 2014-09-17 | Sloan Kettering Inst Cancer | SELECTIVE HDAC HEMMER |
WO2012018499A2 (en) | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
US8859502B2 (en) * | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
ES2568260T3 (es) | 2010-11-16 | 2016-04-28 | Acetylon Pharmaceuticals, Inc. | Compuestos de pirimidin hidroxi amida como inhibidores de proteína desacetilasa y métodos de uso de los mismos |
US8404738B2 (en) | 2011-01-21 | 2013-03-26 | Hoffmann-La Roche Inc. | 4-amino-N-hydroxy-benzamides for the treatment of cancer |
EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
US9512083B2 (en) | 2011-07-20 | 2016-12-06 | The General Hospital Corporation | Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
JP2015515279A (ja) * | 2012-04-19 | 2015-05-28 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療 |
US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
WO2014121062A1 (en) | 2013-02-01 | 2014-08-07 | Acetylon Pharmaceuticals, Inc. | Selective hdac3 inhibitors |
US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
US20140357512A1 (en) | 2013-06-03 | 2014-12-04 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase (hdac) biomarkers in multiple myeloma |
US9403779B2 (en) | 2013-10-08 | 2016-08-02 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors |
JP6584391B2 (ja) | 2013-10-10 | 2019-10-02 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | 非ホジキンリンパ腫を治療するための、hdac阻害剤単独またはpi3k阻害剤との組み合わせ |
ES2862126T3 (es) | 2013-10-10 | 2021-10-07 | Acetylon Pharmaceuticals Inc | Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa |
US20150105409A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating nonhodgkin's lymphoma |
WO2015054175A1 (en) | 2013-10-11 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deactylase inhibitors and immunomodulatory drugs |
JP6535670B2 (ja) | 2013-12-03 | 2019-06-26 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | ヒストンデアセチラーゼ阻害剤と免疫調節薬の組合せ |
EP3084446B1 (en) | 2013-12-20 | 2022-12-14 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma |
US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
-
2015
- 2015-07-06 US US14/792,046 patent/US9833466B2/en active Active
- 2015-07-06 WO PCT/US2015/039225 patent/WO2016007423A1/en active Application Filing
- 2015-07-06 SG SG11201700094TA patent/SG11201700094TA/en unknown
- 2015-07-06 KR KR1020177003321A patent/KR20170044097A/ko unknown
- 2015-07-06 JP JP2017522324A patent/JP6952602B2/ja active Active
- 2015-07-06 BR BR112017000301A patent/BR112017000301A2/pt not_active Application Discontinuation
- 2015-07-06 AU AU2015288060A patent/AU2015288060A1/en not_active Abandoned
- 2015-07-06 CA CA2954522A patent/CA2954522A1/en not_active Abandoned
- 2015-07-06 MX MX2017000307A patent/MX2017000307A/es unknown
- 2015-07-06 CN CN201580047830.2A patent/CN107205988A/zh active Pending
- 2015-07-06 EP EP15818585.0A patent/EP3166603B1/en active Active
- 2015-07-06 EA EA201790142A patent/EA201790142A1/ru unknown
-
2017
- 2017-01-05 IL IL249935A patent/IL249935A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112017000301A2 (pt) | 2017-11-07 |
EP3166603A1 (en) | 2017-05-17 |
EA201790142A1 (ru) | 2017-07-31 |
SG11201700094TA (en) | 2017-02-27 |
EP3166603B1 (en) | 2020-02-12 |
US20160030458A1 (en) | 2016-02-04 |
IL249935A0 (en) | 2017-03-30 |
CN107205988A (zh) | 2017-09-26 |
AU2015288060A1 (en) | 2017-02-09 |
EP3166603A4 (en) | 2017-12-13 |
JP6952602B2 (ja) | 2021-10-20 |
CA2954522A1 (en) | 2016-01-14 |
US9833466B2 (en) | 2017-12-05 |
KR20170044097A (ko) | 2017-04-24 |
JP2017524735A (ja) | 2017-08-31 |
WO2016007423A1 (en) | 2016-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017000307A (es) | Tratamiento de leucemia con inhibidores de histona deacetilasa. | |
PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
PH12016500649A1 (en) | Combinations of histone deactylase inhibitors and immunomodulatory drugs | |
PH12016501015A1 (en) | Combinations of histone deacetylase inhibitors and immunomodulatory drugs | |
MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
MX2017003933A (es) | Metodos de tratamiento de la enfermedad hepatica. | |
MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
PH12015502091A1 (en) | Cdc7 inhibitors | |
SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
MX2015006478A (es) | Inhibidores de glutaminasa y metodos de empleo. | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
TR201901348T4 (tr) | Metap-2 inhibitörleri olarak pirolidinon türevleri. | |
MD20160007A2 (ro) | Inhibitori ai RORC2 şi metode de utilizare a acestora | |
MX2017011018A (es) | Inhibicion de la actividad de olig2. | |
ZA201901367B (en) | Inhibition of olig2 activity | |
PH12016501838A1 (en) | Compounds and their methods of use | |
MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
EA201691907A1 (ru) | Комбинированная терапия кураксинами | |
UA103888U (uk) | Розчин фенолу для ін'єкцій для лікування хронічного больового синдрому |